Literature DB >> 10165824

The economics of osteoporosis and its prevention. A review.

D J Torgerson1, D M Reid.   

Abstract

A systematic review of all published economic evaluations of treatments for the prevention of osteoporosis since 1980 was undertaken. 21 published studies were identified. The majority of the studies were set in the context of the US healthcare system. Non-US studies were heavily influenced by the methodologies of 1 US research group. All studies published before 1990 only considered the use of hormone replacement therapy (HRT) at the menopause for osteoporosis prevention. Since 1990 a number of studies have looked at other therapies as well as HRT in older women. All studies that have made a direct comparison between using HRT at the menopause with HRT in older women have suggested that it is more cost effective to initiate therapy in older non-perimenopausal women. However, there is a paucity of evidence from randomised controlled trials on which to base assumptions on costs and effectiveness. Large randomised trails with hip fracture as the main outcome measure are required to answer key economic and clinical questions.

Entities:  

Mesh:

Year:  1997        PMID: 10165824     DOI: 10.2165/00019053-199711020-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

Review 1.  Economic modelling before clinical trials.

Authors:  David J Torgerson; Sarah Byford
Journal:  BMJ       Date:  2002-07-13

2.  Economics notes: Converting international cost effectiveness data to UK prices.

Authors:  Toby B Gosden; David J Torgerson
Journal:  BMJ       Date:  2002-08-03

Review 3.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

4.  Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Authors:  Olof Johnell; Bengt Jönsson; Linus Jönsson; Dennis Black
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Hip fracture prevention: cost-effective strategies.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  The pharmacoeconomics of hormone replacement therapy.

Authors:  D J Torgerson; D M Reid
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 7.  Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.

Authors:  A J Rosner; D T Grima; G W Torrance; C Bradley; J D Adachi; R J Sebaldt; D J Willison
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

9.  [Proximal femoral fractures in the elderly. Analysis of data from health insurance providers on more than 23 million insured persons--part 1].

Authors:  R Lohmann; U Frerichmann; U Stöckle; T Riegel; M J Raschke
Journal:  Unfallchirurg       Date:  2007-07       Impact factor: 1.000

10.  [Proximal femoral fractures in the elderly. Data from health insurance providers on more than 23 million insured persons--part 2].

Authors:  U Frerichmann; M J Raschke; U Stöckle; S Wöhrmann; R Lohmann
Journal:  Unfallchirurg       Date:  2007-07       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.